Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.78 |
| ▸ | RAB9A | P51151 | 7/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.78 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.62 |
| ▸ | FPR1 | P21462 | 10/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29395943 | 1.00 | NPC1 (0.78) | NPC1RAB9ASMN1; SMN2TDP1ADORA2A | |
| SCHEMBL12238010 | 0.87 | NPC1 (0.77) | NPC1RAB9ASMN1; SMN2TDP1ADORA2A | |
| SCHEMBL2541804 | 0.83 | RAB9A (0.74) | NPC1RAB9ASMN1; SMN2TDP1ADORA2A | |
| SCHEMBL2545819 | 0.82 | SMN1; SMN2 (0.68) | NPC1RAB9ASMN1; SMN2TDP1ADORA2A | |
| SCHEMBL12238007 | 0.80 | SMN1; SMN2 (0.86) | NPC1RAB9ASMN1; SMN2TDP1ADORA2A | |
| SCHEMBL12238006 | 0.80 | MAPT (0.69) | NPC1RAB9ASMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL12941628 | 0.79 | ADORA2A (0.62) | NPC1RAB9ASMN1; SMN2TDP1ADORA2A | |
| SCHEMBL29527731 | 0.77 | SMN1; SMN2 (0.73) | NPC1RAB9ASMN1; SMN2TDP1ADORA2A | |
| SCHEMBL12238033 | 0.74 | SMN1; SMN2 (0.48) | NPC1RAB9ASMN1; SMN2TDP1ADORA2A | |
| SCHEMBL12238032 | 0.73 | SMN1; SMN2 (0.71) | NPC1RAB9ASMN1; SMN2TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2918273-B1 | METHODS AND CELLS FOR IDENTIFYING RIG-I PATHWAY REGULATORS | KINETA INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9458492-B2 | Methods and cells for identifying RIG-I pathway regulators | Kineta, Inc. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458492-B2 | Methods and cells for identifying RIG-I pathway regulators | Kineta, Inc. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9408826-B2 | Isoflavone anti-viral compounds | Kineta, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9408826-B2 | Isoflavone anti-viral compounds | Kineta, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9408826-B2 | Isoflavone anti-viral compounds | Kineta, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| WO-2016073947-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2016-05-12 | — | — | WO | disclosed |
| US-20160122312-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | Kineta, Inc. | 2016-05-05 | — | — | US | disclosed |
| US-20160122312-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | Kineta, Inc. | 2016-05-05 | — | — | US | disclosed |
| EP-2560652-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20130039887-A1 | Methods of Identifying and Using Anti-Viral Compounds | Kineta, Inc. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130039887-A1 | Methods of Identifying and Using Anti-Viral Compounds | Kineta, Inc. (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2012154271-A2 | METHOD AND CELLS FOR IDENTIFYING RIG-I PATHWAY REGULATORS | Kineta, Inc. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012003030-A9 | METHODS OF IDENTIFYING & USING ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012003030-A2 | METHODS OF IDENTIFYING & USING ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20110262482-A1 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262482-A1 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2011133728-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133728-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262482-A1 | ANTI-VIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | NPC1 1706/4885RAB9A 812/4885SMN1; SMN2 2632/4885 |
| US-20130039887-A1 | Methods of Identifying and Using Anti-Viral Compounds | MAVS, EIF2AK2, DDX5 | NPC1 1559/4885RAB9A 1624/4885SMN1; SMN2 1585/4885 |
| US-20160122312-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | MAVS, EIF2AK2, IRF3 | NPC1 750/4885RAB9A 1595/4885SMN1; SMN2 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.